晚期糖基化终末产物受体与肺动脉高压的研究进展  

Research Progress of Advanced Glycation End Product Receptor and Pulmonary Hypertension

作　　者：赵霞迪 谈林华[1] ZHAO Xiadi;TAN Linhua(Department of Surgical Intensive Care Unit,the Children′s Hospital of Zhejiang University School of Medicine,National Child Health and Disease Clinical Research Center,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院外科重症监护病房国家儿童健康与疾病临床医学研究中心,杭州310052

出　　处：《医学综述》2023年第7期1249-1254,共6页Medical Recapitulate

基　　金：国家自然科学基金(81571475)。

摘　　要：肺动脉高压(PH)是一种复杂的进行性破坏性心肺血管疾病,具有高致残率和致死率的特点,目前其发病机制尚未明确,而特异性治疗药物昂贵且无法逆转血管重塑。晚期糖基化终末产物受体(RAGE)是细胞膜上具有多种配体的免疫球蛋白超家族成员,可介导多种肺部疾病。RAGE在不同类型PH中均高表达,不同配体与RAGE结合后通过多种机制介导PH,可溶性RAGE(sRAGE)即可竞争性结合配体,未来sRAGE与其他靶向RAGE的治疗方式或可成为PH治疗的新策略。Pulmonary hypertension(PH)is a complex progressive and destructive cardiopulmonary vascular disease with high morbidity and mortality,with unclear pathogenesis.Specific therapeutic agents are expensive and cannot reverse vascular remodeling.The advanced glycation end product receptor(RAGE),a member of the immunoglobulin superfamily on the cell membrane with multiple ligands,can mediate a variety of lung diseases.High expression of RAGE has been found in different types of PH,and a variety of ligands bind to RAGE and then mediate PH through various mechanisms.The soluble RAGE(sRAGE),binds ligands competitively and may be a new strategy for PH treatment with other therapeutic modalities targeting RAGE.

关 键 词：肺动脉高压 晚期糖基化终末产物受体 肺血管重塑 

分 类 号：R543.2[医药卫生—心血管疾病]